Is Entrada Therapeutics, Inc. (TRDA) a Buy, Sell, or Hold?
NASDAQ : TRDA
Entrada Therapeutics, Inc.
$7.67 USD
$0.63 (8.95%)
- Volume
- 260.81K
- Average Volume
- 406.57K
- Market Capitalization
- $297.75M
- P/E Ratio
- -1.93
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $16.45
- Year Low
- $5.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.89
Company Overview
NASDAQ
Dipal Doshi
Biotechnology
Healthcare
TRDA
152
US
USD
Liquidity Metrics
0.21
10.89
10.89
4.65
0.00
Sales & Valuation
$25.42M
63.54
1.39
-2.22
-3.18
Profitability
-$3.47
-$143.75M
-3537.73%
-3520.25%
-57.61%
-55.47%
P/E Metrics
-1.93
0.03
0.03
Analyst Price Target & Rating
$14.00
$17.00
$11.00
2/5
6 Analysts
-45.21%
Financial Health Scores
-0.15
1/9
$211.33M
$298.88M
$65.47M
-$164.96M
Key Metrics (TTM)
$222.56M
47.49
-1.35
10.89
-57.61%
-62.61%
-55.77%
-50.34%
29 days
Company Executives
| Name | Title |
|---|---|
| Dipal Doshi | Chief Executive Officer & Director |
| Nathan J. Dowden | President & Chief Operating Officer |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Kerry Robert | Senior Vice President of People |
| Sandeep Basnet | Head of Information Technology |
| Jared Cohen | General Counsel |
| Kory James Wentworth | Chief Financial Officer & Treasurer |
| Natarajan Sethuraman | President of Research & Development |
| Kevin Healy | Senior Vice President of Regulatory Affairs |
Poll Results
No votes yet today — be the first to share your view!
About Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, In ... c. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
2026-08-05 10:01:08
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to a loss of $1.04 per share a year ago.
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
2026-08-05 07:00:00
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business updates. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of our DMD franchise,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
2026-06-08 11:08:30
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-04 10:00:00
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-06-02 17:04:00
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-06-02 07:00:00
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201.
2026-06-02 07:00:00
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiation of the Cohort 2 dose at 10 mg/kg, a dose escalation from 5 mg/kg in Cohort 1.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 16:30:00
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Frequently Asked Questions
-
What is the current Entrada Therapeutics, Inc. (TRDA) stock price?
-
Entrada Therapeutics, Inc.(NASDAQ:TRDA) stock price is $7.67 in the last trading session. During the trading session, TRDA stock reached the peak price of $16.45 while $5.02 was the lowest point it dropped to. The percentage change in TRDA stock occurred in the recent session was 8.95% while the dollar amount for the price change in TRDA stock was $0.63.
-
TRDA's industry and sector of operation?
-
The NASDAQ listed TRDA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TRDA?
-
Dipal Doshi | Chief Executive Officer & Director
Nathan J. Dowden | President & Chief Operating Officer
Karla MacDonald | Chief Corporate Affairs Officer
Kerry Robert | Senior Vice President of People
Sandeep Basnet | Head of Information Technology -
How many employees does TRDA have?
-
Number of TRDA employees currently stands at 152. TRDA operates from One Design Center Place, Boston, MA 02210, US.
-
Link for TRDA official website?
-
Official Website of TRDA is: https://www.entradatx.com
-
How do I contact TRDA?
-
TRDA could be contacted at phone #857 520 9158 and can also be accessed through its website. TRDA operates from One Design Center Place, Boston, MA 02210, US.
-
How many shares of TRDA are traded daily?
-
The average number of TRDA shares traded daily for last 3 months was 406.57K.
-
What is the market cap of TRDA currently?
-
The market value of TRDA currently stands at $297.75M with its latest stock price at $7.67